Trials / Completed
CompletedNCT00762645
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Travoprost 0.004% (Travatan) | One drop in each eye, once daily at 9 AM |
| DRUG | Pilocarpine 1% | One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2008-09-30
- Last updated
- 2023-12-06
- Results posted
- 2010-03-15
Source: ClinicalTrials.gov record NCT00762645. Inclusion in this directory is not an endorsement.